CLAIMS

1. Use of a vaccine composition in the manufacture of a medicament for the protection of a human subject against dengue disease caused by a dengue virus of serotype 2, wherein said human subject is aged between 6 and 60 years old and is dengue immune and wherein said composition comprises:

   (i) a dengue antigen of each of serotypes 1 to 4, wherein said dengue antigens of serotypes 1 to 4 are each independently selected from the group consisting of:
      (a) a live attenuated dengue virus; and
      (b) a live attenuated chimeric dengue virus;

   and wherein said medicament results in a statistically significant reduction in the incidence or likelihood of dengue disease caused by a dengue virus of serotype 2.

2. The use according to claim 1, wherein said dengue disease is severe dengue disease.

3. The use according to claim 1 or claim 2, wherein said protection of a human subject results in a reduction in the incidence or likelihood of hospitalisation due to said dengue disease.

4. The use as claimed in claim 1, wherein said human subject is also protected against dengue disease caused by a dengue virus of serotype 1, dengue disease caused by a dengue virus of serotype 3 and dengue disease caused by a dengue virus of serotype 4.

5. The use as claimed in claim 4, wherein said dengue disease caused by a dengue virus of serotype 1 is severe dengue disease, said dengue disease caused by a dengue virus of serotype 2 is severe dengue disease, said dengue disease caused by a dengue virus of serotype 3 is severe dengue disease and said dengue disease caused by a dengue virus of serotype 4 is severe dengue disease.

6. The use according to any preceding claim, wherein said subject is at least 9 years of age.

7. The use according to any preceding claim, wherein said subject is at least 12 years of age.

8. The use according to any preceding claim, wherein said subject is aged between 9 and 60 years old.

9. The use according to any preceding claim, wherein said subject is aged between 12 and 60 years old.

10. The use according to any one of claims 1 to 5, wherein said subject is aged between 6 and 16 years old.

11. The use according to any preceding claim, wherein said subject is aged between 9 and 16 years old.

12. The use according to any preceding claim, wherein said composition comprises a dengue antigen of each of serotypes 1 to 4 and wherein said dengue antigens of serotypes 1, 3 and 4 are each a live attenuated chimeric dengue virus and said dengue antigen of serotype 2 is selected from the group consisting of a live attenuated dengue virus and a live attenuated chimeric dengue virus.

13. The use according to any one of claims 1 to 11, wherein said composition comprises a dengue antigen of each of serotypes 1 to 4 and wherein said dengue antigens of serotypes 1, 3 and 4 are each independently selected from the group consisting of: (a) a live attenuated dengue virus and (b) a live attenuated chimeric dengue virus and said dengue antigen of serotype 2 is a live attenuated chimeric dengue virus.

14. The use according to any preceding claim, wherein said composition comprises a dengue antigen of each of serotypes 1 to 4 and wherein each of said dengue antigens is a live attenuated chimeric dengue virus.

15. The use according to any preceding claim, wherein said live attenuated chimeric dengue virus comprises one or more proteins from a dengue virus and one or more proteins from a different flavivirus.

16. The use according to claim 15, wherein the different flavivirus is an attenuated yellow fever virus.

17. The use according to any preceding claim, wherein the live attenuated chimeric dengue virus comprises a yellow fever virus genome whose prM-E sequence has been substituted with the prM-E sequence of a dengue virus.

18. The use according to any preceding claim, wherein said subject is yellow fever immune.

19. The use according to any preceding claim, wherein said subject resides in a dengue endemic area.

20. The use according to any preceding claim, wherein said medicament is to be administered in three or more doses.

21. The use according to any preceding claim, wherein said dengue disease caused by a dengue virus of serotype 2 is dengue disease caused by a dengue virus of serotype 2 having an American, Asian/American, or a Cosmopolitan genotype.

22. The use according to any preceding claim, wherein said composition further comprises a pharmaceutically acceptable carrier or excipient.